Quinagolide in the management of prolactinoma.

Abstract

OBJECTIVE:

This study reports a six year experience with quinagolide (CV205-502) in the treatment of 40 patients with hyperprolactinemia or prolactinoma.

PATIENTS AND MEASUREMENTS:

Forty patients with hyperprolactinemia were treated with quinagolide (CV 205-502, Norprolac) for 2-72 months (mean 31.6 months). The patient's ages ranged from 12 to 53 years and 90% were female. Seventeen had no radiologic evidence of tumor; 11 had microadenomas; and 12 had macroadenomas.

RESULTS:

All patients had a reduction of the serum prolactin following quinagolide therapy with normalization in 82% with no tumor, 73% with microadenomas, and 67% with macroadenomas. Fifty-five percent of microadenoma and 75% of macroadenoma patients had a decrease in tumor size when assessed by a blinded reviewer. Ten of 38 female patients became pregnant while taking quinagolide. The dosage of quinagolide ranged from 75 to 400 [mgr]g/day with a median dose of 100[mgr]g/day. A comparison of side effects in a subgroup of 35 patients who had taken bromocriptine prior to quinagolide administration showed a greater than 75% reduction in nausea, vomiting, dizziness, and drowsiness during quinagolide administration.

CONCLUSIONS:

We conclude that quinagolide is a safe and effective long-term alternative to bromocriptine therapy, particularly in those individuals with bromocriptine intolerance.

• Authors: P N Schultz, L Ginsberg, I E McCutcheon, N Samaan, M Leavens, R F Gagel
• Journal: Pituitary (Pituitary) Vol. 3 Issue 4 Pg. 239-49 (Dec 2000) ISSN: 1386-341X [Print] United States
• PMID: 11788012 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Aminoquinolines
• Dopamine Agonists
• quinagolide
• Prolactin

Topics

• Adolescent
• Adult
• Aminoquinolines (administration & dosage, adverse effects, therapeutic use)
• Child
• Dopamine Agonists (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Pituitary Neoplasms (drug therapy, pathology)
• Prolactin (blood)
• Prolactinoma (drug therapy, pathology)